YOLFTbeta
QuantumSi Inc

QuantumSi Inc

QSI · NASDAQ · Healthcare / Medical Devices

1.15USD-0.07 (-5.74%)

Price History

Full chart

Market Stats

Previous Close1.22
Open1.23
Day Range1.14 – 1.23
52-Week Range0.69 – 3.10
Volume3.59M
Market Cap182.61M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.46
Dividend Yield0.00%
Beta3.25
50-Day Avg0.7714
200-Day Avg0.9573

About

Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer's protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS. It also provides Platinum analysis software, a cloud-based solution that automates data analysis workflows and visualizes the sequencing results. The company was founded in 2013 and is headquartered in Branford, Connecticut.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Jeffrey Alan Hawkins
  • Employees145
  • Headquarters29 Business Park Drive, Branford, CT, United States, 06405, USA
  • Websitehttps://www.quantum-si.com

Leadership

  • Mr. Jeffrey Alan HawkinsPresident, CEO & Director · b. 1978
  • Dr. Jonathan M. Rothberg Ph.D.Founder & Executive Director · b. 1964
  • Mr. Todd RearickChief Technology Officer
  • Dr. Christian Lapointe J.D., Ph.D.General Counsel & Corporate Secretary · b. 1972
  • Ms. Lindsay ThompsonChief Human Resources Officer

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue000459.00K1.08M3.06M2.44M
Growth (%)----+135.73%+182.62%-20.34%
Cost of Revenue-894.00K1.04M2.58M594.00K1.46M1.28M
Gross Profit--894.00K-1.04M-2.58M488.00K1.60M1.15M
Gross Margin----562.96%45.10%52.32%47.33%
Operating Expense-35.80M95.87M121.26M111.66M110.18M98.51M
Operating Income-36.62M-36.69M-96.91M-123.84M-111.17M-108.58M-97.36M
Operating Margin----26980.61%-10274.58%-3550.56%-3996.72%
EBITDA-35.84M-35.80M-93.94M-111.77M-91.80M-96.35M-92.91M
EBITDA Margin----24351.63%-8484.66%-3150.78%-3813.88%
Net Income-35.80M-36.61M-94.99M-132.44M-95.96M-101.01M-101.34M
Net Income Margin----28854.47%-8868.76%-3303.04%-4160.06%
R&D28.10M27.55M46.58M72.06M67.03M59.64M53.76M
R&D as % of Total Revenue---15699.78%6194.55%1950.33%2206.86%
Interest Expense09.00K5.00K13.25M0--
Interest Expense % of Total Revenue---2885.84%0.00%--

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets37.41M40.59M503.23M391.49M298.25M247.87M245.61M
Total Liabilities1.93M4.50M26.19M32.78M26.63M32.45M25.38M
Total Equity35.46M36.09M477.03M358.71M271.62M215.42M220.23M
Cash32.93M36.91M35.78M84.32M133.86M49.24M21.64M
Total Debt-1.75M8.08M17.45M15.30M12.95M4.17M
Net Debt-32.93M-35.16M-27.71M-66.87M-118.56M-36.29M-17.47M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-30.71M-32.57M-66.81M-90.56M-94.04M-87.80M-94.72M
Investing Cash Flow-1.24M-461.00K-450.94M137.19M143.43M-32.67M-28.32M
Financing Cash Flow18.22M37.01M516.63M1.91M149.00K35.88M95.42M
Capital Expenditure1.24M461.00K5.76M10.74M5.27M4.58M2.52M
Free Cash Flow-31.95M-33.03M-72.58M-101.30M-99.31M-92.38M-97.23M
FCF to OCF104.04%101.42%108.63%111.86%105.61%105.22%102.66%

Earnings

Report DateAug 3, 2020Nov 13, 2020Mar 30, 2021May 24, 2021Aug 16, 2021Nov 10, 2021Feb 28, 2022May 9, 2022Aug 8, 2022Nov 7, 2022Mar 6, 2023May 11, 2023Aug 7, 2023Nov 9, 2023Feb 29, 2024May 9, 2024Aug 7, 2024Nov 12, 2024Feb 26, 2025May 15, 2025Aug 5, 2025Nov 5, 2025Mar 3, 2026May 7, 2026Aug 13, 2026Nov 4, 2026
EPS Estimate0.000.00----0.17-0.17-0.17-0.19-0.20-0.20-0.16-0.17-0.18-0.18-0.17-0.16-0.18-0.19-0.17-0.13-0.17-0.12-0.10-0.13-0.13
EPS Actual0.000.00-0.01-0.70-3.05-0.13-0.21-0.25-0.21-0.23-0.24-0.17-0.15-0.15-0.16-0.12-0.15-0.16-0.16-0.11-0.11-0.17-0.08-0.09-0.11-
Surprise-----23.53%-23.53%-47.06%-10.53%-15.00%-20.00%-6.25%11.76%16.67%11.11%29.41%6.25%11.11%13.89%35.29%15.38%0.00%38.20%10.00%15.38%-
Timing----After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap182.61M
Enterprise Value57.84M
Trailing P/E0.00
Forward P/E0.00
Price / Sales113.78
Price / Book0.92
EPS-0.46
Book Value0.823
Revenue (TTM)1.60M
Gross Profit (TTM)562.00K
EBITDA-87.36M
Profit Margin0.00%
Operating Margin-7450.29%
Return on Equity-49.11%
Return on Assets-25.72%
Shares Outstanding198.95M
Shares Float180.22M
Beta3.25
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 3 analystsTarget 2.30
  • Strong Buy
    1
  • Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
24.82%
Insiders
10.45%
Retail / Other
64.73%

Top Institutional Holders

  • BlackRock Inc
    13.41M6.13%
  • Vanguard Capital Management, LLC
    7.02M3.21%
  • ARK Investment Management LLC
    6.88M3.14%
  • Sumitomo Mitsui Trust Group Inc
    3.89M1.77%
  • Amova Asset Management Americas, Inc
    3.89M1.77%
  • Geode Capital Management, LLC
    3.84M1.75%
  • State Street Corp
    3.77M1.72%
  • Millennium Management LLC
    3.13M1.43%
  • AQR Capital Management LLC
    2.39M1.09%
  • UBS Group AG
    1.70M0.78%
  • Vanguard Portfolio Management, LLC
    1.52M0.69%
  • Susquehanna International Group, LLP
    1.46M0.67%
  • Northern Trust Corp
    1.26M0.58%
  • Vanguard Fiduciary Trust Co
    1.12M0.51%
  • Fosun International Ltd
    743.93K0.34%

Top Fund Holders

  • ARK Genomic Revolution ETF
    7.16M3.27%
  • Vanguard MStar Total Stk Mkt Idx Invest
    5.35M2.45%
  • Amova ARK Pstv Chg Innovt P JPY Acc
    3.20M1.46%
  • iShares Biotechnology ETF
    1.27M0.58%
  • Fidelity Extended Market Index
    1.23M0.56%